The US Food and Drug Administration (FDA) has granted orphan drug status to Merrimack Pharmaceuticals' MM-398 as a treatment for pancreatic cancer. MM-398 is a stable nanotherapeutic encapsulation of chemotherapy drug irinotecan. MM-398 has partnered with PharmaEngine for de
The US Food and Drug Administration (FDA) has granted orphan drug status to Merrimack Pharmaceuticals’ MM-398 as a treatment for pancreatic cancer.
MM-398 is a stable nanotherapeutic encapsulation of chemotherapy drug irinotecan.
MM-398 has partnered with PharmaEngine for development and commercialisation in Taiwan under the designation PEP02.
